Law360, New York (September 15, 2010, 12:06 PM ET) -- GlaxoSmithKline PLC has won a bid to purge all claims related to one patent in a putative class action brought by employee benefit plans that accuses the drugmaker of filing baseless infringement suits in an effort to delay generic competition for the antidepressant Wellbutrin SR.
Judge Lawrence Stengel of the U.S. District Court for the Eastern District of Pennsylvania on Monday denied GSK's motion for summary judgment as to all of the indirect purchasers' claims, but granted the pharmaceutical giant's motion to dismiss claims regarding U.S....
GSK Gets Patent Cut From Wellbutrin Antitrust Action
To view the full article, take a free trial now.
